Alex Goldberg

Bristol-Myers Squibb Company (NYSE:BMY) and Xerox Corporation (NYSE:XRX) Added to Equity Profile Report's NYSE Decliners Watch List.

 
Repost This

Wilmington, DE -- (SBWIRE) -- 02/26/2014 -- Equity Profile Report expands its NYSE Decliners Weekly Watch List adding Bristol-Myers Squibb Company (NYSE:BMY) and Xerox Corporation (NYSE:XRX).

Bristol-Myers Squibb Company (NYSE:BMY) a company that discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide closed down in its previous session (-1.16%) on 7,250,352 shares traded as FDA approved Bristol-Myers drug for rare body fat disorder. Bristol-Myers Squibb Company (NYSE:BMY) is currently down (-5.42%) from its recent 52-week high which has prompted Equity Profile Report to add the stock to their NYSE Decliners Watch List.

Click Here to find out what other Investors are saying about Bristol-Myers Squibb Company (NYSE:BMY)

Xerox Corporation (NYSE:XRX) a company that provides business process and document management solutions worldwide closed down in its previous session (-1.02%) on 10,814,507 shares traded after Xerox Selected to Implement PatientPoint Technology to Help Improve Healthcare. Xerox Corporation (NYSE:XRX) is currently down (-15.81%) from its recent 52-week high which has prompted Equity Profile Report to add the stock to their NYSE Decliners Watch List.

Click Here to find out what other Investors are saying about Xerox Corporation (NYSE:XRX)

Equityprofilereport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities.

Through a vast network of IR professionals Equityprofilereport.com is often aware of several large investor awareness campaigns being deployed.

Timing is important when trading Small Caps and Penny Stocks.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.Equityprofilereport.com

Disclosure
Equityprofilereport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit Equityprofilereport.com website, for complete risks and disclosures.

Contact Info:
Equity Profile Report
editor@Equityprofilereport.com